Les Ulis, July the 8th, 2011: LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled “Monoclonal Antibodies with Enhanced ADCC Function” on April 26, 2011, by the U.S. Patent and Trademark Office (USPTO). The new patent covers monoclonal antibodies having an enhanced antibody-dependent cellular cytotoxicity (ADCC) due to an improved glycosylation profile for fucose.

Commenting on this important development, LFB’s CEO Christian Béchon stated, “We are very pleased to expand our patent coverage in this promising area of monoclonal antibody technology. This U.S. patent is key to furthering our development of a portfolio of monoclonal antibodies”.

The Patented Technology
The patented monoclonal antibodies promise to increase therapeutic effectiveness of many monoclonal antibodies. The patented monoclonal antibodies have greater therapeutic effectiveness due to enhanced antibody-dependent cellular cytotoxicity (ADCC). This results from an improved glycosylation profile that increases interaction with effector cells after the monoclonal antibody binds to a target cell. The patented monoclonal antibodies have increased binding to the receptors of effector cells such as macrophage, TH lymphocyte, and NK cells. The patented technology will help solve a long-standing problem of monoclonal antibodies having poor therapeutic effectiveness despite high specificity to target cells.

LFB has developed in clinical trials two monoclonal antibodies with this promising new technology : LFB-R593, (Roledumab) a monoclonal antibody targeting alloimmunization in expectant mothers that are Rhesus negative with a baby that is Rhesus positive, and LFB-R603 (Ublituximab), an anti-CD20 monoclonal antibody targeting chronic lymphocytic leukemia

About LFB
LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Hemostasis, Immunology and Intensive Care. The LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at the international level and develop innovative therapies. In 2010, the LFB Group reported total turnover of 411.6 million euros, up 9.6%, and invested 86.5 million euros in product development.

Press contact
LFB Sandrine Charrières - Corporate communication director